Evidence map›Paper›PMID 35576813›Full record

ReviewCurrent opinion in chemical biology2022

Emerging frontiers in virtual drug discovery: From quantum mechanical methods to deep learning approaches.

Christoph Gorgulla, Abhilash Jayaraj, Konstantin Fackeldey, Haribabu Arthanari

Abstract readReview
In one paragraph

Review in Current opinion in chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. The impact of Library Size and Scale of Testing on Virtual Screening.bioRxiv : the preprint server for biology · 2024
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christoph GorgullaDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School (HMS), Boston, MA, USA; Department of Physics, Faculty of Arts and Sciences, Harvard University, Cambridge, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA.
Abhilash JayarajWesleyan University, Chemistry Department, Middletown, CT, USA.
Konstantin FackeldeyInstitute of Mathematics, Technical University Berlin, Berlin, Germany; Zuse Institute Berlin, Berlin, Germany.
Haribabu ArthanariDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School (HMS), Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA. Electronic address: hari_arthanari@hms.harvard.edu.

Funding

STRUCTURE BASIS OF IMMUNE-CELL SURFACE RECEPTOR FUNCTIONR01AI037581 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WAGNER, GERHARD · 1996 to 2021
$6.7M
CONTROL AND ACTIVATION OF THE TUMOR NECROSIS FACTOR RECEPTORSR01AI150709 · NIAID · HARVARD MEDICAL SCHOOL · PI WAGNER, GERHARD, WU, HAO · 2020 to 2024
$4.0M
NMR Fingerprinting: Leveraging optimal control pulse design, tailored isotope labeling, and machine learning to study intractable proteinsR01GM136859 · NIGMS · DANA-FARBER CANCER INST · PI ARTHANARI, HARIBABU · 2020 to 2024
$2.4M
Roles of Eukaryotic Translation Initiation Factors in Gene ExpressionR01CA200913 · NCI · HARVARD MEDICAL SCHOOL · PI WAGNER, GERHARD · 2016 to 2020
$2.3M
Next Generation Solution NMR Techniques for GPCR Structure, Dynamics and FunctionR01GM129026 · NIGMS · HARVARD MEDICAL SCHOOL · PI WAGNER, GERHARD · 2018 to 2021
$2.0M
An MD-MSM Study of Allosterism on the DNA Repair Protein MutSR15GM129715 · NIGMS · WESLEYAN UNIVERSITY · PI BEVERIDGE, DAVID LEWIS · 2018 to 2018
$488k
Librational Mode Coupling Theory of Allosteric Signal TransmissionR15GM144870 · NIGMS · WESLEYAN UNIVERSITY · PI BEVERIDGE, DAVID LEWIS · 2022 to 2022
$482k
NCI NIH HHS R01 CA200913NIAID NIH HHS R01 AI037581NIAID NIH HHS R01 AI150709NIGMS NIH HHS R01 GM129026NIGMS NIH HHS R01 GM136859NIGMS NIH HHS R15 GM129715NIGMS NIH HHS R15 GM144870
6 · The paper itself

Abstract

Virtual screening-based approaches to discover initial hit and lead compounds have the potential to reduce both the cost and time of early drug discovery stages, as well as to find inhibitors for even challenging target sites such as protein-protein interfaces. Here in this review, we provide an overview of the progress that has been made in virtual screening methodology and technology on multiple fronts in recent years. The advent of ultra-large virtual screens, in which hundreds of millions to billions of compounds are screened, has proven to be a powerful approach to discover highly potent hit compounds. However, these developments are just the tip of the iceberg, with new technologies and methods emerging to propel the field forward. Examples include novel machine-learning approaches, which can reduce the computational costs of virtual screening dramatically, while progress in quantum-mechanical approaches can increase the accuracy of predictions of various small molecule properties.

Indexed as

Deep LearningDrug DiscoveryLigandsMachine LearningProteinsLigandsProteinsADMETDrug discoveryLigand preparationMachine learningMolecular dockingQuantum chemistryStructure-based virtual screensUltra-large virtual screens

Identifiers

PMID35576813
PMCPMC9990419

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.